New injection targets hidden heart risk in early trial

NCT ID NCT07551505

Not yet recruiting Disease control Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of BSA204, an experimental injection, in 40 Chinese adults with borderline high lipoprotein(a) – a fatty substance linked to heart disease. The main goal is to check safety and side effects, while also measuring changes in cholesterol levels after six months. Because it's a Phase 1 trial, success is not guaranteed, but results could guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BSA204 injection
What this could lead to: If safe and effective, BSA204 could become a new treatment to lower high lipoprotein(a) levels, potentially reducing heart disease risk.
What could go wrong: This is a very early Phase 1 trial with only 40 people. It primarily checks safety, not effectiveness. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS

Contacts and locations

Locations

Peking University First Hospital

Beijing, Beijing Municipality, China
Peking University First Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.